Aliases & Classifications for Breast Disease

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 12 15 17
Breast Diseases 54 42 44 70

Classifications:



External Ids:

Disease Ontology 12 DOID:3463
ICD9CM 34 610-612.99
MeSH 44 D001941
NCIt 50 C26709
SNOMED-CT 67 79604008
UMLS 70 C0006145

Summaries for Breast Disease

MedlinePlus : 42 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary : Breast Disease, also known as breast diseases, is related to microglandular adenosis and hypertrophy of breast, and has symptoms including pruritus, exanthema and pelvic pain. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Acetylcholine and Tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include breast, thyroid and lymph node, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and Increased viability with paclitaxel

Disease Ontology : 12 A thoracic disease that is located in the breast.

Wikipedia : 73 Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain,... more...

Related Diseases for Breast Disease

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 453)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 32.8 TP53 PGR ESR1 ERBB2
2 hypertrophy of breast 32.2 TP53 PGR ESR1 ERBB2 BRCA1
3 in situ carcinoma 31.7 TP53 PGR ESR1 ERBB2 EGF BRCA1
4 breast fibroadenoma 31.7 TP53 TFF1 PGR ESR1 ERBB2 CTSD
5 ductal carcinoma in situ 31.6 VEGFA TP53 PGR ESR2 ESR1 ERBB2
6 papilloma 31.4 VEGFA TP53 ERBB2 CASP3
7 lobular neoplasia 31.2 TP53 PRLR PGR ESR2 ESR1 ERBB2
8 breast cancer 31.2 VEGFA TP53 TNF TFF1 RHOC PRLR
9 gynecomastia 31.2 PGR ESR2 ESR1 ERBB2
10 mammographic density 31.1 IGFBP3 IGF1 ESR1 CYP1B1 CYP1A1 COMT
11 intraductal papilloma 31.0 PGR ESR1 ERBB2
12 breast ductal carcinoma 30.9 VEGFA TP53 TFF1 PGR ESR2 ESR1
13 female breast cancer 30.8 TP53 TNF PGR IGFBP3 IGF1 ESR1
14 endometriosis 30.8 VEGFA PGR MIR199A1 ESR2 ESR1 CYP1B1
15 mammary paget's disease 30.8 PGR ESR1 ERBB2
16 insulin-like growth factor i 30.7 IGFBP3 IGF1 ESR1 EGF
17 leiomyoma 30.6 PGR ESR2 ESR1 EGF COMT
18 bilateral breast cancer 30.6 TP53 PGR ESR1 ERBB2 BRCA1
19 tubular adenocarcinoma 30.6 PGR ESR1 ERBB2
20 adenocarcinoma 30.5 VEGFA TP53 ERBB2 EGF BRCA1
21 breast malignant phyllodes tumor 30.4 TP53 PGR ESR1 ERBB2
22 prostatic hypertrophy 30.4 PGR ESR1 EGF
23 inflammatory breast carcinoma 30.4 RHOC PGR ESR1 ERBB2
24 cystitis 30.4 VEGFA TP53 TNF EGF
25 galactorrhea 30.4 PRLR IGF1
26 vascular disease 30.4 VEGFA TP53 TNF MIR199A1 IGF1 CASP3
27 meningioma, familial 30.4 VEGFA TP53 PGR ESR1 EGF CTSD
28 body mass index quantitative trait locus 11 30.4 VEGFA TNF MIR199A1 IGFBP3 IGF1 ESR1
29 estrogen excess 30.4 PGR ESR2 ESR1
30 apocrine adenocarcinoma 30.4 PGR ESR1 ERBB2
31 fasciitis 30.4 TP53 TNF ESR1
32 sporadic breast cancer 30.4 TP53 PGR ESR2 ESR1 ERBB2 BRCA1
33 li-fraumeni syndrome 30.4 TP53 ESR1 ERBB2 BRCA1
34 fallopian tube carcinoma 30.4 VEGFA TP53 PGR ESR1 ERBB2 BRCA1
35 breast carcinoma in situ 30.3 VEGFA TP53 PGR ESR1 ERBB2 EGF
36 skin melanoma 30.3 VEGFA TP53 TNF MIR199A1 ERBB2 EGF
37 ovarian disease 30.3 VEGFA TP53 TNF PGR MIR199A1 IGF1
38 infertility 30.2 PRLR PGR ESR2 ESR1 CYP1A1
39 intracranial meningioma 30.0 PGR ESR1
40 mastitis 11.2
41 diabetic mastopathy 11.0
42 multiple fibroadenomas of the breast 11.0
43 rare non-malformative breast disease 10.9
44 infant gynecomastia 10.9
45 breast abscess 10.9
46 fat necrosis of breast 10.8
47 breast angiomatosis 10.8
48 intrahepatic cholestasis of pregnancy 10.7 TP53 TNF ESR2 ESR1 CYP1B1 CYP1A1
49 mixed cell adenoma 10.7 IGF1 ESR1 EGF CTSD
50 asperger syndrome 10.7 IGF1 ESR2 ESR1 CYP1B1 CYP1A1 COMT

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease

Symptoms & Phenotypes for Breast Disease

UMLS symptoms related to Breast Disease:


pruritus; exanthema; pelvic pain; mastodynia; breast engorgement; nipple discharge; signs and symptoms in breast; other signs and symptoms in breast; breast pain female

GenomeRNAi Phenotypes related to Breast Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.26 CASP3 ESR1 ESR2 TNF
2 Increased viability with paclitaxel GR00179-A-1 8.32 CASP3

MGI Mouse Phenotypes related to Breast Disease:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.46 BRCA1 CASP3 COMT CTSD CYP1A1 EGF
2 homeostasis/metabolism MP:0005376 10.45 BRCA1 CASP3 COMT CTSD CYP1A1 CYP1B1
3 cellular MP:0005384 10.43 BRCA1 CASP3 CTSD ERBB2 ESR1 ESR2
4 growth/size/body region MP:0005378 10.42 BRCA1 CASP3 CTSD CYP1A1 EGF ERBB2
5 behavior/neurological MP:0005386 10.41 BRCA1 CASP3 COMT CTSD ERBB2 ESR1
6 cardiovascular system MP:0005385 10.37 BRCA1 CASP3 COMT ERBB2 ESR1 ESR2
7 immune system MP:0005387 10.36 BRCA1 CASP3 COMT CTSD CYP1A1 EGF
8 hematopoietic system MP:0005397 10.35 BRCA1 CASP3 COMT CTSD CYP1A1 ESR1
9 integument MP:0010771 10.34 BRCA1 CASP3 CTSD EGF ERBB2 ESR1
10 digestive/alimentary MP:0005381 10.32 BRCA1 CASP3 CTSD EGF ERBB2 ESR1
11 neoplasm MP:0002006 10.25 BRCA1 CYP1B1 ERBB2 ESR1 ESR2 IGF1
12 embryo MP:0005380 10.22 BRCA1 COMT ERBB2 ESR1 PGR PRLR
13 limbs/digits/tail MP:0005371 10.22 BRCA1 ERBB2 ESR1 ESR2 IGF1 IGFBP3
14 nervous system MP:0003631 10.22 BRCA1 CASP3 COMT CTSD ERBB2 ESR1
15 adipose tissue MP:0005375 10.21 BRCA1 ESR1 ESR2 IGF1 IGFBP3 PRLR
16 muscle MP:0005369 10.2 BRCA1 CASP3 ERBB2 ESR1 ESR2 IGF1
17 normal MP:0002873 10.02 BRCA1 CYP1A1 EGF ERBB2 ESR1 ESR2
18 no phenotypic analysis MP:0003012 9.97 CASP3 CYP1A1 ESR1 ESR2 PGR TNF
19 reproductive system MP:0005389 9.97 BRCA1 CASP3 COMT EGF ERBB2 ESR1
20 renal/urinary system MP:0005367 9.86 BRCA1 CASP3 COMT ESR1 ESR2 IGF1
21 respiratory system MP:0005388 9.65 BRCA1 CASP3 COMT ERBB2 ESR1 ESR2
22 skeleton MP:0005390 9.4 BRCA1 CASP3 ERBB2 ESR1 ESR2 IGF1

Drugs & Therapeutics for Breast Disease

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Tamoxifen Approved Phase 4 10540-29-1 2733526
3
Tocopherol Approved, Investigational Phase 4 1406-66-2
4
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
5
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
6 Tocotrienol Investigational Phase 4 6829-55-6
7 abobotulinumtoxinA Phase 4
8 Neurotransmitter Agents Phase 4
9 Cholinergic Agents Phase 4
10 Botulinum Toxins Phase 4
11 Botulinum Toxins, Type A Phase 4
12 retinol Phase 4
13 Retinol palmitate Phase 4
14 Evening Primrose Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Antirheumatic Agents Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Lipid Regulating Agents Phase 4
19 Dermatologic Agents Phase 4
20 Hypolipidemic Agents Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22 Estrogen Receptor Modulators Phase 4
23 Chelating Agents Phase 4
24 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 4
25 Analgesics Phase 4
26 Omega 3 Fatty Acid Phase 4
27 Vitamins Phase 4
28 Tocopherols Phase 4
29 Tocotrienols Phase 4
30
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
31
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
32
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
33
Epirubicin Approved Phase 2, Phase 3 56420-45-2 41867
34
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
35
tannic acid Approved Phase 3 1401-55-4
36
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
37
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
38
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
39
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
40
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
41
Acetaminophen Approved Phase 3 103-90-2 1983
42
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 3 14838-15-4 26934
43
Codeine Approved, Illicit Phase 3 76-57-3 5284371
44
Ibuprofen Approved Phase 3 15687-27-1 3672
45
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
46
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
47
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
48 Immunologic Factors Phase 2, Phase 3
49 Alkylating Agents Phase 2, Phase 3
50 Anti-Bacterial Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Randomized, Open, Parallel Controlled Clinical Study on the Efficacy and Safety of the Treatment of Cyclomastopathy With Xiaoru Sanjie Capsule Unknown status NCT02929420 Phase 4 Xiaoru Sanjie capsules;Xiao Yao pills
2 The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
3 Single-shot Pectoral Plane (PECs) Blocks Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECs Block and Local Anaesthetic Infusion After Non-ambulatory Breast Cancer Surgery: A Prospective, Randomised, Double-blind Trial Completed NCT03024697 Phase 4
4 A Single Blinded Randomized Controlled Trial of the Comparative Effects of Tamoxifen and Evening Primrose Oil in Premenopausal Non-high Risk Patients With Benign Breast Disease With Respect to the Estrogen Receptor Status. Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
5 Contrast Enhanced Breast MRI: Comparison of Two Macrocyclic Gadolinium-Based Contrast Agents: Gadoterate Meglumine (Dotarem) and Gadobutrol (Gadavist). A Prospective Study. Not yet recruiting NCT03730051 Phase 4 Gadoterate meglumine;Gadobutrol
6 Omega-3 Fatty Acids Plus Vitamin E Cosupplementation Versus Vitamin E in Fibrocystic Breast Patient Not yet recruiting NCT04694027 Phase 4 Omega 3 fatty acid;VitaE
7 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen™ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease Unknown status NCT00237523 Phase 3 IoGen (molecular iodine)
8 Randomized Controlled Trials of Diet and Lifestyle Intervention to Promote Chinese Postpartum Women's Health Unknown status NCT01039051 Phase 2, Phase 3
9 Prospective Randomized Controlled Study on the Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer Unknown status NCT03373708 Phase 2, Phase 3 Epirubicin;Cyclophosphamide;Docetaxel;Goserelin acetate;Tamoxifen;Letrozole
10 Monitored Anesthesia Care Using Remifentanil and Ketofol Results in a Superior Quality of Recovery Compared With Total Intravenous Anesthesia in Ambulatory Breast Augmentation Completed NCT03764267 Phase 3 Remifentanil;general anesthetic
11 A Multicenter, Randomized, Open-label, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. Versus Charcotrace Inj. in Patients With Nonpalpable Breast Lesions Completed NCT04606329 Phase 3 LuminoMark inj.(Conc. for fluorescence);Charcotrace Inj.
12 A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3® for the Treatment of Pain After Breast Surgery. Completed NCT00299039 Phase 3 acetaminophen plus codeine;acetaminophen plus ibuprofen
13 BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer Completed NCT00039780 Phase 3 BNP7787;Placebo
14 Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial Completed NCT01591746 Phase 3 Botulinum Toxin Type A;Placebo
15 Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease Completed NCT00967681 Phase 3
16 Electronic Patient Reported Outcome Measures (ePROMs) in Patients With Breast Disease: An Open-label, Randomized Controlled Trial on Patient Reported Experience Measures (PREMs) and Effectivity (PREMs_PROMs) Recruiting NCT04718324 Phase 3
17 A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer Recruiting NCT01917279 Phase 3 Docetaxel plus Capecitabine;Intermittent Capecitabine;Metronomic Capecitabine
18 Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System Unknown status NCT02511301 Phase 1, Phase 2
19 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
20 A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast Unknown status NCT00036998 Phase 2
21 A Multicenter, Open-label, Parallel, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. (Conc. for Fluorescence) Localization in Patients With Nonpalpable Breast Lesions Completed NCT03743259 Phase 2 LuminoMark inj. 0.1mL;LuminoMark inj. 0.2mL;Charcotrace Inj.
22 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease Completed NCT00744276 Phase 2 danazol;Placebo
23 A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer Completed NCT00050427 Phase 2 ET743;ET743
24 Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer Completed NCT01472146 Phase 2 Zo-Nantax
25 Guaraná ("Paullinia Cupana") for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study Completed NCT01043913 Phase 2 Guarana extract
26 TARGIT-E(Elderly) Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer Completed NCT01299987 Phase 2
27 A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancers Recruiting NCT03709446 Phase 1, Phase 2 Leflunomide
28 A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HeR-positive, Her2-positive Metastatic Breast Cancer Recruiting NCT03304080 Phase 1, Phase 2 Anastrozole;Palbociclib;Trastuzumab;Pertuzumab
29 A Single-arm, Multi-center Phase II Clinical Study of Pyrotinib Combined With Vinorelbine in the Treatment of HER2-positive and Treated Metastatic Breast Cancer Recruiting NCT04605575 Phase 2 Pyrotinib 320mg + Vinorelbine;Pyrotinib 400mg + Vinorelbine;Pyrotinib plus Vinorelbine
30 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
31 A Randomized, Multicenter, Phase II Study of the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Recruiting NCT03500380 Phase 2 RC48-ADC;Lapatinib;Capecitabine
32 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Recruiting NCT03979508 Phase 2 Abemaciclib
33 A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer Not yet recruiting NCT03910712 Phase 2 Pyrotinib;Trastuzumab;Aromatase inhibitor
34 Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the First-line Treatment of Advanced HER2-positive/HR-positive Breast Cancer Phase II Study Not yet recruiting NCT04088110 Phase 2 Pyrotinib;Trastuzumab;Aromatase Inhibitors
35 GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer Terminated NCT01499160 Phase 2 letrozole;lapatinib;everolimus
36 A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) Unknown status NCT02909452 Phase 1 Entinostat;Pembrolizumab
37 A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer Completed NCT00620594 Phase 1 BEZ235
38 Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas Completed NCT00028496 Phase 1
39 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat
40 Proton Magnetic Resonance Spectroscopy of Normal Breast Tissues in Women Volunteers Unknown status NCT00155090
41 Expedited Discharge of Patients Undergoing Pedicled TRAM Flap Breast Reconstruction Procedure in Ambulatory Surgical Facility: Quality of Recovery Outcomes Unknown status NCT01438268
42 Clinical Application of Breast Blood-oxygen Functional Imaging Technology Unknown status NCT01678170
43 A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery Unknown status NCT01654432
44 THE EFFECTS OF VITAMIN D ON MAMMOGRAPHIC DENSITY AND BREAST TISSUE Unknown status NCT02239874
45 Early Detection of Breast Disease Using Medical Radiometer - RTM - 01 - RES Unknown status NCT02286583
46 Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer Unknown status NCT01140763
47 A Randomized Study Evaluating the Safety and Effects of the Combination of Palbociclib With Epirubicin and Cyclophosphamide Followed by Paclitaxel as Neoadjuvant Therapy in Triple Negative Breast Cancer Unknown status NCT03756090 Palbociclib;Placebo oral capsule;Epirubicin;Cyclophosphamide;Paclitaxel
48 Effectiveness of Cell Phone Counseling to Improve Breast Feeding Indicators Unknown status NCT01383070
49 Prospective, Multi-centre, Observational Trial Evaluating Outcomes of Immediate Breast Reconstruction Using an Implant and Acellular Dermal Matrix (SurgiMend) or Autologous Tissue Unknown status NCT02557906
50 The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease. Completed NCT01687790

Search NIH Clinical Center for Breast Disease

Cochrane evidence based reviews: breast diseases

Genetic Tests for Breast Disease

Anatomical Context for Breast Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Disease:

19
Breast

MalaCards organs/tissues related to Breast Disease:

40
Breast, Thyroid, Lymph Node, Prostate, Skin, Ovary, Endothelial

Publications for Breast Disease

Articles related to Breast Disease:

(show top 50) (show all 4850)
# Title Authors PMID Year
1
Strengths and limitations of video-conference multidisciplinary management of breast disease during the COVID-19 pandemic. 61 42
33640926 2021
2
Tuberculosis of the breast: analysis of 17 cases. 42
33654509 2020
3
Antimicrobial potential of Copaiba Oil (Copaifera multijuga Hayne-Leguminosae) against bubaline mastitis multiresistant isolates. 42
33331447 2020
4
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. 54 61
19308726 2010
5
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. 61 54
19551864 2010
6
Cells with minimal expression of the JAK/STAT pathway related proteins STAT5a and the prolactin receptor: evidence of an alternate prolactin receptor isoform in breast disease. 54 61
20214633 2010
7
Nipple aspirate fluid collection, related factors and relationship between carcinoembryonic antigen in nipple aspirate fluid and breast diseases in women in Harbin, PRC. 61 54
19273481 2009
8
Estrogen alpha and progesterone receptor expression in the normal mammary epithelium in relation to breast cancer risk. 61 54
18798271 2009
9
Caffeine consumption and the risk of breast cancer in a large prospective cohort of women. 54 61
18852405 2008
10
[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR]. 54 61
19087676 2008
11
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. 61 54
17851763 2008
12
Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. 54 61
18379196 2008
13
A comparison of plasma versus histologic indices of angiogenic markers in breast cancer. 61 54
18091379 2007
14
Importance of novel sequence alterations in the FHIT gene on formation of breast cancer. 54 61
18338496 2007
15
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]. 61 54
17557253 2007
16
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. 54 61
17417639 2007
17
Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. 54 61
17431282 2007
18
IGFBP3 mRNA expression in benign and malignant breast tumors. 61 54
17210081 2007
19
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. 61 54
17164758 2007
20
[Role of immunocytochemistry in fine needle aspiration cytology diagnosis of mammary lesions of breast]. 54 61
17374259 2006
21
Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. 54 61
16808847 2006
22
Hormones and progeny of breast tumor cells. 54 61
16698656 2006
23
Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. 61 54
16327431 2005
24
[Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. 61 54
15946491 2005
25
Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast. 61 54
15508191 2004
26
Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. 61 54
15217931 2004
27
p65 and c-erbB2 genes expression in breast tumors: comparison with some histological typing, grading and clinical staging. 61 54
12866575 2003
28
Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer. 61 54
12402341 2002
29
Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. 54 61
11839578 2002
30
Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders. 54 61
12699101 2002
31
Breast cancer risk factors and HER2 over-expression in tumors. 61 54
12132871 2001
32
Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. 61 54
11282289 2000
33
Serum c-erbB-2 protein in breast cancer patients. 54 61
10998842 2000
34
Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. 61 54
10836299 2000
35
Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. 54 61
10753193 2000
36
Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. 54 61
10845280 2000
37
Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. 54 61
10720070 2000
38
RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. 61 54
10845277 2000
39
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. 61 54
10637239 2000
40
Angiogenic growth factors in preinvasive breast disease. 54 61
10537355 1999
41
The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. 61 54
10548314 1999
42
HER-2/neu (c-erb-B2) gene and protein in breast cancer. 54 61
10396301 1999
43
Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. 61 54
10442920 1999
44
Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; results from a prospective study. 61 54
10629636 1999
45
Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. 54 61
10363992 1999
46
Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. 54 61
10350435 1999
47
[Relationship of estrogen and progesterone receptors to the menstrual cycle and menopausal status at the time of breast surgery]. 61 54
10486879 1999
48
Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer. 54 61
9772278 1998
49
Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. 61 54
9760013 1998
50
Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. 54 61
9731732 1998

Variations for Breast Disease

Expression for Breast Disease

Search GEO for disease gene expression data for Breast Disease.

Pathways for Breast Disease

Pathways related to Breast Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 VEGFA TP53 TNF RHOC IGF1 ESR2
2
Show member pathways
13.71 VEGFA TP53 RHOC IGF1 ESR2 ESR1
3
Show member pathways
13.55 VEGFA TP53 TNF PRLR IGF1 ERBB2
4
Show member pathways
13.37 VEGFA TP53 TNF PRLR ERBB2 EGF
5
Show member pathways
13.26 VEGFA TNF IGF1 ESR2 ESR1 ERBB2
6
Show member pathways
13.22 TP53 TNF RHOC PRLR IGF1 ERBB2
7
Show member pathways
12.86 VEGFA TP53 IGF1 ERBB2 EGF CASP3
8
Show member pathways
12.75 VEGFA TP53 TNF PRLR IGF1 ERBB2
9 12.73 VEGFA TP53 IGF1 ESR2 ESR1 ERBB2
10
Show member pathways
12.72 TP53 TNF IGF1 CTSD CASP3
11 12.71 VEGFA TP53 TNF IGF1 ERBB2 EGF
12
Show member pathways
12.67 TP53 IGF1 ESR2 ESR1 CASP3 BRCA1
13
Show member pathways
12.63 VEGFA TP53 IGF1 ERBB2 EGF
14
Show member pathways
12.6 TP53 IGF1 ESR2 ESR1 ERBB2 EGF
15
Show member pathways
12.59 TP53 PGR IGF1 ESR2 ESR1 ERBB2
16
Show member pathways
12.44 PRLR ESR2 ESR1 ERBB2 CTSD CASP3
17
Show member pathways
12.4 VEGFA RHOC EGF CASP3
18 12.4 VEGFA TP53 MIR199A1 ERBB2 CYP1B1 CASP3
19
Show member pathways
12.37 TP53 IGFBP3 IGF1 CASP3 BRCA1
20
Show member pathways
12.32 TP53 IGF1 ERBB2 EGF
21
Show member pathways
12.23 TFF1 IGF1 ESR2 ESR1 ERBB2 EGF
22 12.19 VEGFA TNF ESR2 CASP3
23 12.17 VEGFA TP53 TNF EGF CASP3
24
Show member pathways
12.16 TNF MIR199A1 IGF1 EGF
25
Show member pathways
12.15 VEGFA TFF1 PGR IGFBP3 IGF1 ESR2
26 12.12 VEGFA TP53 ESR1 CASP3 BRCA1
27 12 TP53 TNF RHOC CASP3
28 11.96 TP53 RHOC IGF1 EGF
29 11.95 VEGFA IGF1 ERBB2 EGF
30
Show member pathways
11.91 PRLR PGR ESR1 ERBB2 EGF
31 11.79 VEGFA IGF1 EGF
32 11.74 TP53 ERBB2 CASP3 BRCA1
33
Show member pathways
11.73 VEGFA PRLR ESR1
34 11.73 VEGFA TP53 ERBB2 EGF
35
Show member pathways
11.71 CYP1B1 CYP1A1 COMT
36 11.7 TP53 ERBB2 BRCA1
37 11.67 TNF IGF1 EGF
38 11.63 VEGFA IGFBP3 CASP3
39 11.57 IGF1 CYP1B1 CYP1A1
40 11.54 VEGFA IGF1 EGF
41 11.54 TNF CYP1B1 CYP1A1
42 11.53 VEGFA TP53 CASP3 BRCA1
43 11.51 TP53 CASP3 BRCA1
44
Show member pathways
11.5 TFF1 ESR1 BRCA1
45 11.48 TNF EGF CTSD
46 11.48 VEGFA TP53 TNF IGF1 ESR1 ERBB2
47 11.45 TP53 ESR1 CTSD
48 11.4 TP53 TNF CASP3
49 11.39 VEGFA TP53 IGFBP3
50
Show member pathways
11.34 CYP1B1 CYP1A1 COMT

GO Terms for Breast Disease

Cellular components related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 9.33 VEGFA IGF1 EGF
2 insulin-like growth factor ternary complex GO:0042567 8.96 IGFBP3 IGF1
3 insulin-like growth factor binding protein complex GO:0016942 8.62 IGFBP3 IGF1

Biological processes related to Breast Disease according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.23 VEGFA TP53 TNF PGR ESR2 ESR1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 VEGFA TP53 TNF PGR IGF1 ESR2
3 positive regulation of transcription, DNA-templated GO:0045893 10.04 TP53 TNF IGF1 ESR2 ESR1 EGF
4 cytokine-mediated signaling pathway GO:0019221 9.97 VEGFA TP53 TNF PRLR CASP3
5 positive regulation of apoptotic process GO:0043065 9.93 TP53 TNF IGFBP3 CYP1B1 CTSD CASP3
6 positive regulation of angiogenesis GO:0045766 9.88 VEGFA MIR199A1 CYP1B1 BRCA1
7 negative regulation of gene expression GO:0010629 9.85 VEGFA TP53 TNF PGR IGF1 ESR1
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 VEGFA TNF IGF1
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 VEGFA TP53 IGF1 EGF
10 positive regulation of endothelial cell migration GO:0010595 9.81 VEGFA MIR199A1 EGF
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 VEGFA TNF IGF1 EGF
12 positive regulation of epithelial cell proliferation GO:0050679 9.8 VEGFA IGF1 ERBB2
13 response to estrogen GO:0043627 9.8 ESR1 COMT BRCA1
14 positive regulation of neuron apoptotic process GO:0043525 9.79 TP53 TNF CASP3
15 positive regulation of protein complex assembly GO:0031334 9.79 VEGFA TNF RHOC
16 positive regulation of cell adhesion GO:0045785 9.77 VEGFA TNF ERBB2
17 response to antibiotic GO:0046677 9.73 TP53 CYP1A1 CASP3
18 cellular response to organic cyclic compound GO:0071407 9.73 TNF CYP1B1 CYP1A1 CASP3
19 estrogen metabolic process GO:0008210 9.72 CYP1B1 CYP1A1 COMT
20 positive regulation of MAP kinase activity GO:0043406 9.71 VEGFA TNF ERBB2 EGF
21 positive regulation of gene expression GO:0010628 9.7 VEGFA TP53 TNF IGF1 ERBB2 EGF
22 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.66 TP53 ESR1
23 omega-hydroxylase P450 pathway GO:0097267 9.66 CYP1B1 CYP1A1
24 response to salt stress GO:0009651 9.65 TP53 TNF
25 positive regulation of protein localization to early endosome GO:1902966 9.65 VEGFA EGF
26 mammary gland alveolus development GO:0060749 9.65 VEGFA ESR1 EGF
27 toxin metabolic process GO:0009404 9.64 CYP1B1 CYP1A1
28 negative regulation of ERBB signaling pathway GO:1901185 9.61 ERBB2 EGF
29 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.6 VEGFA TP53
30 positive regulation of epithelial tube formation GO:1905278 9.58 VEGFA EGF
31 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.5 TP53 TNF ESR1
32 intracellular steroid hormone receptor signaling pathway GO:0030518 9.43 PGR ESR2 ESR1
33 positive regulation of MAPK cascade GO:0043410 9.35 VEGFA IGFBP3 IGF1 ERBB2 EGF
34 positive regulation of protein kinase B signaling GO:0051897 9.1 VEGFA TNF MIR199A1 ESR1 ERBB2 EGF

Molecular functions related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.03 VEGFA TP53 TNF PGR ESR2 ESR1
2 growth factor activity GO:0008083 9.62 VEGFA TFF1 IGF1 EGF
3 nuclear receptor activity GO:0004879 9.58 PGR ESR2 ESR1
4 estrogen 16-alpha-hydroxylase activity GO:0101020 9.46 CYP1B1 CYP1A1
5 estrogen receptor activity GO:0030284 9.37 ESR2 ESR1
6 steroid binding GO:0005496 9.33 PGR ESR2 ESR1
7 estrogen response element binding GO:0034056 9.26 ESR2 ESR1
8 steroid hormone receptor activity GO:0003707 9.13 PGR ESR2 ESR1
9 enzyme binding GO:0019899 9.1 TP53 PGR ESR2 ESR1 CYP1A1 BRCA1

Sources for Breast Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....